Significant Progress Made on the Trivalent Recombinant Protein...
- Written by LATEST ASIANET NEWS RELEASES
- Published in Asia Net
CHENGDU, China, Feb. 20, 2023 /PRNewswire-AsiaNet/ -- Recently, with the support of the National Key R&D Program of China, following the clinical trial approval for Recombinant Variant COVID-19 Vaccine (Sf9 cell) approved by NMPA, WestVac Biopharma (Guangzhou) Co., Ltd. (hereinafter referred to as "W...
Authors: LATEST ASIANET NEWS RELEASES
